Quinoline and thiazolopyridine allosteric inhibitors of MALT1

被引：13

作者：

Scott, David A. ^{[1
,2
]}

Hatcher, John M. ^{[1
,2
]}

Liu, Hongyan ^{[5
]}

Fu, Mingpeng ^{[5
]}

Du, Guangyan ^{[1
,2
]}

Fontan, Lorena ^{[3
]}

Us, Ilkay ^{[3
]}

Casalena, Gabriella ^{[3
]}

Qiao, Qi ^{[4
]}

Wu, Hao ^{[4
]}

Melnick, Ari ^{[3
]}

Gray, Nathanael S. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA

[2] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, 360 Longwood Ave, Boston, MA 02115 USA

[3] Cornell Univ, Div Hematol & Oncol, Dept Med, Weill Cornell Med, New York, NY 10021 USA

[4] Harvard Med Sch, Program Cellular & Mol Med, Boston Childrens Hosp, Boston, MA 02115 USA

[5] PepTech Shanghai Pharmaceut Corp, 388 Yindu Rd, Shanghai 200231, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2019年 / 29卷 / 14期

关键词：

MALT1; Protease inhibitors; Allosteric; B-cell lymphomas; PROTEASE;

D O I：

10.1016/j.bmcl.2019.05.040

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Quinolines and thiazolopyridines were developed as allosteric inhibitors of MALT1, with good cellular potency and exquisite selectivity. Mouse pharmacokinetic (PK) profiling showed these to have low in vivo clearance, and moderate oral exposure. The thiazolopyridines were less lipophilic than the quinolines, and one thiazolopyridine example was active in our hIL10 mouse pharmacodynamic (PD) model upon oral dosing.

引用

页码：1694 / 1698

页数：5

共 50 条

[31] THERAPEUTICS Assault on MALT1
Burgess, Darren J.
NATURE REVIEWS CANCER, 2013, 13 (02) : 80 - 81
[32] MALT1 regulates LUBAC
Ioana Visan
Nature Immunology, 2015, 16 (12) : 1214 - 1214
[33] Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase
Haifinger, Stephan
Lenz, Georg
Thome, Margot
CURRENT OPINION IN CHEMICAL BIOLOGY, 2014, 23 : 47 - 55
[34] MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies
Liang, Xuewu
Cao, YiChun
Li, Chunpu
Yu, Haolan
Yang, Chenghua
Liu, Hong
MEDICINAL RESEARCH REVIEWS, 2021, 41 (04) : 2388 - 2422
[35] The MALT1 switch in autoimmunity
Maria Papatriantafyllou
Nature Reviews Immunology, 2012, 12 (12) : 807 - 807
[36] Allosteric activation of MALT1 by its ubiquitin-binding Ig3 domain
Schairer, Rebekka
Hall, Gareth
Zhang, Ming
Cowan, Richard
Baravalle, Roberta
Muskett, Frederick W.
Coombs, Peter J.
Mpamhanga, Chido
Hale, Lisa R.
Saxty, Barbara
Iwaszkiewicz, Justyna
Decaillet, Chantal
Perroud, Mai
Carr, Mark D.
Thome, Margot
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (06) : 3093 - 3102
[37] Effects of MALT1 Inhibitors on cutaneous T-cell lymphoma cells
Mayo, J.
Velatooru, L.
Wang, X.
Duvic, M.
Ni, X.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S272 - S272
[38] Development of selective small molecule inhibitors of cellular MALT1 protease activity
Oberg, Fredrik G.
Karlstrom, Sofia
Henderson, Ian
Hewitt, Ellen
Kallin, Anders
Sedig, Susanne
Lindberg, Jimmy
Sohlenius-Sternbeck, Anna-Karin
Bethell, Richard
Albertella, Mark
CANCER RESEARCH, 2016, 76
[39] Natural Product Inhibitors of the Arginine-Specific Protease Activity of MALT1
Castro, A.
Smith, E. A.
Krumpe, Haugh L. R.
O'Keefe, B. R.
Staudt, L. M.
McMahon, J. B.
Gustafson, K. R.
PLANTA MEDICA, 2013, 79 (10) : 845 - 845
[40] MALT1 Rearrangements in BAL Fluid
Borie, Raphael
Wislez, Marie
Fleury-Feith, Jocelyne
Delfau-Larue, Marie-Helene
Cadranel, Jacques
CHEST, 2012, 142 (01) : 262 - 262

← 1 2 3 4 5 →